JPMorgan Chase & Co. Purchases 1,215 Shares of Natus Medical Inc. (BABY)
JPMorgan Chase & Co. boosted its position in shares of Natus Medical Inc. (NASDAQ:BABY) by 1.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 97,565 shares of the company’s stock after buying an additional 1,215 shares during the period. JPMorgan Chase & Co. owned 0.30% of Natus Medical worth $3,688,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Neuberger Berman Group LLC increased its position in shares of Natus Medical by 9.9% in the second quarter. Neuberger Berman Group LLC now owns 1,572,351 shares of the company’s stock worth $59,435,000 after buying an additional 141,770 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Natus Medical by 9.6% in the second quarter. Bank of New York Mellon Corp now owns 1,001,484 shares of the company’s stock worth $37,858,000 after buying an additional 87,938 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in shares of Natus Medical by 13.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 953,413 shares of the company’s stock worth $36,640,000 after buying an additional 112,582 shares during the last quarter. State Street Corp increased its stake in shares of Natus Medical by 2.2% in the first quarter. State Street Corp now owns 674,379 shares of the company’s stock worth $25,914,000 after buying an additional 14,617 shares during the last quarter. Finally, Pax World Management LLC increased its stake in shares of Natus Medical by 15.0% in the second quarter. Pax World Management LLC now owns 430,000 shares of the company’s stock worth $16,254,000 after buying an additional 56,100 shares during the last quarter. 88.00% of the stock is currently owned by hedge funds and other institutional investors.
Natus Medical Inc. (NASDAQ:BABY) traded down 0.25% during midday trading on Monday, hitting $40.55. The stock had a trading volume of 7,791 shares. The company has a market cap of $1.32 billion, a P/E ratio of 34.96 and a beta of 0.78. The firm’s 50-day moving average price is $41.01 and its 200 day moving average price is $37.02. Natus Medical Inc. has a 12 month low of $29.54 and a 12 month high of $51.05.
Natus Medical (NASDAQ:BABY) last posted its quarterly earnings data on Wednesday, July 20th. The company reported $0.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.03. Natus Medical had a return on equity of 13.82% and a net margin of 10.20%. The firm earned $96 million during the quarter, compared to analysts’ expectations of $92.71 million. During the same period in the prior year, the business earned $0.34 EPS. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, analysts expect that Natus Medical Inc. will post $1.55 earnings per share for the current fiscal year.
A number of equities research analysts have weighed in on the company. Raymond James Financial Inc. upgraded Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 target price for the company in a report on Tuesday, September 13th. Zacks Investment Research downgraded Natus Medical from a “buy” rating to a “hold” rating in a report on Wednesday, September 28th. Finally, Benchmark Co. assumed coverage on Natus Medical in a report on Tuesday, October 4th. They issued a “buy” rating and a $55.00 target price for the company.
In related news, insider James B. Hawkins bought 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 28th. The stock was bought at an average cost of $38.48 per share, for a total transaction of $384,800.00. Following the acquisition, the insider now directly owns 459,725 shares of the company’s stock, valued at approximately $17,690,218. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.80% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc. (NASDAQ:BABY).
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.